Loading institutional data...
Loading institutional data...
Held by 232 of 5,944 reporting institutions (93th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
How management deployed cash over 9 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Modest payoff on reinvested capital. Current ROIC on all capital: 1%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 9 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $74M covers all $3M of scheduled principal — no refinancing pressure. Scheduled principal only (excludes interest & revolver draws). As of 2026-01-31 (10-K).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~261.7% on $3M of debt.
Cash vs short-term debt unavailable.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $10.28 today, the market must believe free cash flow compounds 0.6%/yr for a decade (off $46M normalized FCF).
The market's 0.6% is more conservative than its 1-yr track record.
2-stage DCF · 0.06B shares · net debt -$71M
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
5/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Needs granular two-year detail (receivables, PP&E, D&A, SG&A) — not fully reported.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor; leverage rising year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on $68M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
EOD close · as of 2026-09-17
No material risks flagged.
Is the profit real, and how strong is the balance sheet?
FY2026 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|
| R&D | 14.4 | 14.9 | 15.2 | 24.5 | 32.5 | 31.5 | 28.0 | 25.3 |
| SG&A | 20.1 | 24.4 | 27.2 | 32.2 | 28.6 | 22.4 | 18.2 | 16.6 |
| Operating Income | -9.5 | -12.3 | -17.3 | -54.8 | -62.9 | -38.3 | -13.8 | -1.4 |
| Income Tax | 0.0 | -1.4 | 0.0 | 0.1 | 0.2 | 0.4 | 0.6 | -2.3 |
| Net Income | -15.1 | -16.3 | -18.4 | -55.4 | -62.7 | -38.4 | -13.9 | 0.5 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on PHR: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2026
Each value shows its share of revenue below it (common-size).
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $480.6M 100.0% | $419.8M 100.0% | $356.3M 100.0% | $280.9M 100.0% | $213.2M 100.0% | $148.7M 100.0% | $124.8M 100.0% | $99.9M 100.0% | $79.8M 100.0% |
| Research & Development | $121.5M 25.3% | $117.4M 28.0% | $112.3M 31.5% | $91.2M 32.5% | $52.3M 24.5% | $22.6M 15.2% | $18.6M 14.9% | $14.3M 14.4% | $11.4M 14.3% |
| Selling, General & Admin | $79.9M 16.6% | $76.6M 18.2% | $79.9M 22.4% | $80.4M 28.6% | $68.7M 32.2% | $40.5M 27.2% | $30.5M 24.4% | $20.1M 20.1% | $18.8M 23.6% |
| Total Operating Expenses | $487.2M 101.4% | $477.9M 113.8% | $492.8M 138.3% | $457.5M 162.9% | $330.1M 154.8% | $174.3M 117.3% | $140.1M 112.3% | $109.4M 109.5% | $94.4M 118.2% |
| Operating Income | -$6.6M -1.4% | -$58.1M -13.8% | -$136.5M -38.3% | -$176.6M -62.9% | -$116.8M -54.8% | -$25.7M -17.3% | -$15.3M -12.3% | -$9.5M -9.5% | -$14.6M -18.2% |
| Interest Expense | $7.0M 1.4% | $2.3M 0.6% | $1.9M 0.5% | $1.4M 0.5% | $1.2M 0.5% | $1.7M 1.1% | $3.0M 2.4% | $3.5M 3.5% | — |
| Interest & Investment Income | $2.2M 0.5% | $2.7M 0.6% | $4.1M 1.1% | $2.5M 0.9% | — | — | — | — | — |
| Other Income (Expense), net | -$2.3M -0.5% | $2.3M 0.5% | $1.1M 0.3% | $889K 0.3% | -$1.2M -0.5% | -$1.6M -1.1% | -$6.8M -5.4% | -$5.6M -5.6% | -$3.6M -4.6% |
| Pretax Income | -$8.9M -1.9% | -$55.8M -13.3% | -$135.3M -38.0% | -$175.7M -62.5% | -$118.0M -55.3% | -$27.2M -18.3% | -$22.1M -17.7% | -$15.1M -15.1% | -$18.2M -22.8% |
| Income Tax Expense | -$11.2M -2.3% | $2.7M 0.6% | $1.5M 0.4% | $483K 0.2% | $182K 0.1% | $49K 0.0% | -$1.8M -1.4% | $0 0.0% | $0 0.0% |
| Net Income | $2.3M 0.5% | -$58.5M -13.9% | -$136.9M -38.4% | -$176.1M -62.7% | -$118.2M -55.4% | -$27.3M -18.4% | -$20.3M -16.3% | -$15.1M -15.1% | -$18.2M -22.8% |
| Per Share | |||||||||
| EPS (Basic) | $0.04 | $-1.02 | $-2.51 | $-3.36 | $-2.37 | $-0.69 | $-4.50 | — | — |
| EPS (Diluted) | $0.04 | $-1.02 | $-2.51 | $-3.36 | $-2.37 | $-0.69 | $-4.50 | — | — |
| Weighted Avg Shares (Basic) | 59.7M | 57.6M | 54.6M | 52.4M | 49.9M | 39.5M | 20.3M | — | — |
| Weighted Avg Shares (Diluted) | 61.5M | 57.6M | 54.6M | 52.4M | 49.9M | 39.5M | 20.3M | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| PHR | $614M | 257.0× | 21.9× | 1.3× | 14.5% | — | 0.5% | 0.7% | 0.7% | 0.1× | 232 |
Peers = companies sharing PHR's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.